Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Synnott, Naoise C
33  Ergebnisse:
Personensuche X
?
1

Targeting mutant p53 with arsenic trioxide: A preclinical s..:

Rajaram, Subhasree ; Synnott, Naoise C. ; Crown, John..
Translational Oncology.  46 (2024)  - p. 102025 , 2024
Link: https://doi.org/10.1016/..
 
?
2

Targeting p53 for the treatment of cancer:

Duffy, Michael J. ; Synnott, Naoise C. ; O'Grady, Shane.
Seminars in Cancer Biology.  79 (2022)  - p. 58-67 , 2022
Link: https://doi.org/10.1016/..
 
?
3

Characterizing the tumor microenvironment in rare renal can..:

Synnott, Naoise C ; Poeta, Maria Luana ; Costantini, Manuela...
The Journal of Pathology: Clinical Research.  8 (2021)  1 - p. 88-98 , 2021
Link: https://doi.org/10.1002/..
 
?
4

Tracing Lung Cancer Risk Factors Through Mutational Signatu..:

Landi, Maria Teresa ; Synnott, Naoise C ; Rosenbaum, Jennifer...
American Journal of Epidemiology.  190 (2020)  6 - p. 962-976 , 2020
Link: https://doi.org/10.1093/..
 
?
5

COTI-2 reactivates mutant p53 and inhibits growth of triple..:

Synnott, Naoise C. ; O'Connell, David ; Crown, John.
Breast Cancer Research and Treatment.  179 (2019)  1 - p. 47-56 , 2019
Link: https://doi.org/10.1007/..
 
?
6

HER2-Targeted Tyrosine Kinase Inhibitors Cause Therapy-Indu..:

McDermott, Martina S. J. ; Conlon, Neil ; Browne, Brigid C....
Cancers.  11 (2019)  2 - p. 197 , 2019
Link: https://doi.org/10.3390/..
 
?
7

Mutant p53 as a therapeutic target for the treatment of tri..:

Synnott, Naoise C. ; Bauer, Matthias R. ; Madden, Stephen...
Cancer Letters.  414 (2018)  - p. 99-106 , 2018
Link: https://doi.org/10.1016/..
 
?
8

Mutant p53 in breast cancer: potential as a therapeutic tar..:

Duffy, Michael J. ; Synnott, Naoise C. ; Crown, John
Breast Cancer Research and Treatment.  170 (2018)  2 - p. 213-219 , 2018
Link: https://doi.org/10.1007/..
 
?
9

The Mutant p53-Targeting Compound APR-246 Induces ROS-Modul..:

Synnott, Naoise C. ; Madden, Stephen F. ; Bykov, Vladimir J.N....
Translational Oncology.  11 (2018)  6 - p. 1343-1349 , 2018
Link: https://doi.org/10.1016/..
 
?
10

Mutant p53 as a target for cancer treatment:

Duffy, Michael J. ; Synnott, Naoise C. ; Crown, John
European Journal of Cancer.  83 (2017)  - p. 258-265 , 2017
Link: https://doi.org/10.1016/..
 
?
11

Vitamin D analogues: Potential use in cancer treatment:

Duffy, Michael J. ; Murray, Alyson ; Synnott, Naoise C...
Critical Reviews in Oncology/Hematology.  112 (2017)  - p. 190-197 , 2017
Link: https://doi.org/10.1016/..
 
?
12

p53 as a target for the treatment of cancer:

Duffy, Michael J. ; Synnott, Naoise C. ; McGowan, Patricia M....
Cancer Treatment Reviews.  40 (2014)  10 - p. 1153-1160 , 2014
Link: https://doi.org/10.1016/..
 
?
13

Characterizing the tumor microenvironment in rare renal can..:

Synnott, Naoise C ; Poeta, Maria Luana ; Costantini, Manuela...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8682943/.  , 2021
Link: http://www.ncbi.nlm.nih...
 
?
14

Tracing Lung Cancer Risk Factors Through Mutational Signatu..:

Landi, Maria Teresa ; Synnott, Naoise C ; Rosenbaum, Jennifer...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8316614/.  , 2020
Link: http://www.ncbi.nlm.nih...
 
?
15

HER2-Targeted Tyrosine Kinase Inhibitors Cause Therapy-Indu..:

McDermott, Martina SJ ; Conlon, Neil ; Browne, Brigid C...
qt3v78g131.  , 2019
Link: https://escholarship.org..
 
1-15